Company Description
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally.
The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure.
In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments.
It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
| Country | United States |
| Founded | 2000 |
| IPO Date | Aug 5, 2005 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,050 |
| CEO | Michael H. Carrel |
Contact Details
Address: 7555 Innovation Way Mason, Ohio 45040 United States | |
| Phone | 513-755-4100 |
| Website | atricure.com |
Stock Details
| Ticker Symbol | ATRC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001323885 |
| CUSIP Number | 04963C209 |
| ISIN Number | US04963C2098 |
| Employer ID | 34-1940305 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Michael H. Carrel | Chief Executive Officer, President and Director |
| Angela L. Wirick CPA | Chief Financial Officer |
| Douglas J. Seith | Chief Operating Officer |
| Salvatore Privitera J.D. | Chief Technical Officer |
| Karl S. Dahlquist CCEP, J.D. | Chief Legal Officer |
| Dr. Vinayak Doraiswamy Ph.D. | Chief Scientific Officer |
| Valerie Storch-Willhaus | Vice President of Corporate Marketing and Communications |
| Justin J. Noznesky | Chief Marketing and Strategy Officer |
| Deborah Yount | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | SD | Form - SD |
| May 14, 2024 | 8-K | Current Report |
| May 2, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | 144 | Filing |
| May 1, 2024 | 8-K | Current Report |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 144 | Filing |